论文部分内容阅读
目的:探讨恶性淋巴瘤并发白血病的并发率、疗效及预后。方法:收集1983年4月至1997年10月经病理及骨髓检查确诊的淋巴瘤并发白血病33例,其中非霍奇金淋巴瘤(NHL)32例,霍奇金病(HD)1例。采用化疗或局部联合60钴放疗。结果:总有效率为33.3%,其中CR12.1%、PR21.2%。1年生存率为45%,其中高、中、低度NHL并发白血病的1年生存率分别为26.7%、50%、85.7%,中位生存期10个月。结论:并发白血病者全组为16.2%,NHL为21.6%,HD为1.78%;高度恶性,年龄小于30岁,B症状,脾肿大,末梢血白细胞数大于10×109/L等因素与易并发白血病有关。恶性淋巴瘤并发白血病者预后差。
Objective: To investigate the incidence, efficacy and prognosis of malignant lymphoma complicated with leukemia. Methods: Thirty-three cases of lymphoma and leukemia confirmed by pathology and bone marrow examination from April 1983 to October 1997 were collected. Among them, 32 were non-Hodgkin’s lymphoma (NHL) and 1 was Hodgkin’s disease (HD). Chemotherapy or local combination of 60 cobalt radiotherapy. Results: The total effective rate was 33.3%, of which CR12.1% and PR21.2%. The 1-year survival rate was 45%. The 1-year survival rates of high, medium and low NHL were 26.7%, 50% and 85.7%, respectively. The median survival time was 10 months. Conclusions: All patients with leukemia were 16.2%, NHL was 21.6% and HD was 1.78%. Patients with high grade malignancy, younger than 30 years old, B symptoms, splenomegaly, and peripheral blood leukocytes more than 10 × 109 / L Associated with leukemia. Malignant lymphoma with leukemia poor prognosis.